For the Technology Agency of the Czech Republic (TA CR) it is good news that in this important document for the Czech Republic the OECD repeatedly mentions the TA CR and its work. ῞For us it is an indicator that the work which we carry out is at least comparable with other economically developed countries. It doesn’t often happen that a state organisation after not quite six years following its foundation is mentioned in OECD documents as an example of good practice″ said Martin Bunček, deputy chairman of the TA CR.
The Technology Agency of the Czech Republic welcomes the idea of addressing the EU´s innovation deficit. We have studied the proposal prepared by RTD Taskforce. Here are few remarks concerning the key questions, as mentioned in the document presented in the EC proposal.
On 27th April 2016, the Technology Agency of the Czech Republic (TA CR) launched the third call for proposals in research and experimental development (hereinafter the call) for the Program of support for applied research and experimental development DELTA (hereinafter the DELTA programme) and according to the law no. 130/2002 Coll. on support of research, experimental development and innovation from the public funds and on amendement of certain related acts (hereinafter LSRD), according to the Framework for State aid for research, development and innovation (2014 / C 198/01) and in accordance with the Commission Regulation (EU) No. 651/2014 dated on June 17, 2014.
The winners of the fifth annual Cooperation of the Year awards are the Central European Institute of Technology at Brno University of Technology, the start-up AtomTrace and Tescan Brno with the Sci-Trace project. These entities’ cooperation on the development of a globally unique solution for analysing materials was recently recognised by the Association for Foreign Investmen and the American Chamber of Commerce in the Czech Republic together with partners. The fact that in three out of four winning projects solvers teams were supported by TA CR is highly satisfying.
The Association of Innovative Pharmaceutical Industry would like to point out the new opportunity for Czech research teams and companies dealing with those research areas. Newly launched Call 9 of The European initiative IMI2 offers the perfect opportunity for the research teams and companies by applying their researches and results in joint projects with the pharmaceutical industry and European research leaders.